Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-MUC1C-ALLO1 in Advanced or Metastatic Solid Tumors
NCT05239143Phase 1Active, not recruiting
- Sponsor
- Poseida Therapeutics
- Start
- Feb 2022
- Primary completion
- Apr 2039
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of p-muc1c-allo1 in breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC) and 6 more (8 arms), sponsored by Poseida Therapeutics. Primary endpoints: Maximum Tolerated Dose and/or Recommended Phase 2 Dose at Day 28, Overall safety and tolerability profile at 15 years and 1 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
p-muc1c-allo1
03
Conditions
breast cancerovarian cancernon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05239143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239143.